

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers dynamic spinal visualization, including, but not limited to, digital motion x-ray of the spine, including digitization of spinal x-rays and computerized analysis of the back or spine, to be **investigational*** for all indications.

Based on review of available data, the Company considers cineradiography, also known as videofluoroscopy, when used to visualize movement of the back or spine, to be **investigational*** for all indications.

Based on review of available data, the Company considers vertebral motion analysis to be **investigational***.

Policy Guidelines

Cineradiography/videofluoroscopy can be used once per anatomic area with modifier -59 (distinct procedural service) appended to the code when it is used for additional anatomic regions.

These procedures have both a technical and a professional component.

Background/Overview

Flexion/Extension Radiography

Dynamic spinal visualization and vertebral motion analysis are proposed for individuals who are being evaluated for back or neck pain and are being considered for standard flexion/extension radiographs. Flexion/extension radiographs may be performed with a passive external force or by the patient's own movement. Typically, radiographs are taken at the end ranges of flexion and extension and the intervertebral movements (rotation and translation) are measured to assess spinal instability. Flexion/extension radiographs may be used to assess radiographic instability in order to diagnose and determine the most effective treatment (eg, physical therapy, decompression, or spinal fusion) or to assess the efficacy of spinal fusion.

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross Blue Shield Association. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

Dynamic Spinal Visualization

Digital Motion X-Ray

Most spinal visualization technologies use x-rays to create images either on film, video monitor, or computer screen. Digital motion x-ray involves the use of film x-ray or computer-based x-ray "snapshots" taken in sequence as a patient moves. Film x-rays are digitized into a computer for manipulation, while computer-based x-rays are automatically created in a digital format. Using a computer program, the digitized snapshots are then sequenced and played on a video monitor, creating a moving image of the inside of the body. This moving image can then be evaluated by a physician alone or by using computer software that evaluates several aspects of the body's structure, such as intervertebral flexion and extension, to determine the presence or absence of abnormalities.

Videofluoroscopy and Cineradiography

Videofluoroscopy and cineradiography are different names for the same procedure, which uses fluoroscopy to create real-time video images of internal structures of the body. Unlike standard x-rays, which take a single picture at 1 point in time, fluoroscopy provides motion pictures of the body. The results of these techniques can be displayed on a video monitor as the procedure is being conducted, as well as recorded, to allow computer analysis or evaluation at a later time. Like digital motion x-ray, the results can be evaluated by a physician alone or with the assistance of computer software.

Dynamic Magnetic Resonance Imaging

Dynamic magnetic resonance imaging (MRI) is also being developed to image the cervical spine. This technique uses an MRI-compatible stepless motorized positioning device and a real-time true fast imaging with steady-state precession sequence to provide passive kinematic imaging of the cervical spine. The quality of the images is lower than a typical MRI sequence but is proposed to be adequate to observe changes in the alignment of vertebral bodies, the width of the spinal canal, and the spinal cord. Higher-resolution imaging can be performed at the end positions of flexion and extension.

Vertebral Motion Analysis

Vertebral motion analysis systems like the KineGraph VMA (Vertebral Motion Analyzer) provide assisted bending with fluoroscopic imaging and computerized analysis. The device uses facial recognition software to track vertebral bodies across the images. Proposed benefits of the vertebral motion analysis are a reduction in patient-driven variability in bending and assessment of vertebral movement across the entire series of imaging rather than at the end range of flexion and extension.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2012, the KineGraph VMA^{TM‡} (Vertebral Motion Analyzer; Ortho Kinematics) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process (K133875). The system includes a Motion Normalizer^{TM‡} for patient positioning, standard fluoroscopic imaging, and automated image recognition software. Processing of scans by Ortho Kinematics is charged

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

separately. Table 1 lists a sampling of the spinal visualization and motion analysis devices currently cleared by the FDA. FDA product code: LLZ.

Table 1. Spinal Visualization and Motion Analysis Devices Cleared by the U.S. Food and Drug Administration

Device	Manufacturer	Date Cleared	510(k) No.	Indication
SuRgical Planner (SRP) BrainStorm	Surgical Theater, Inc.	07/17/2020	K201465	For use in spinal visualization and motion analysis for neck and back pain
Bone VCAR (BVCAR)	GE Medical Systems SCS	4/8/2019	K183204	For use in spinal visualization and motion analysis for neck and back pain
mediCAD 4.0	mediCAD Hectec Gmbh	9/7/2018	K170702	For use in spinal visualization and motion analysis for neck and back pain
VirtuOst Vertebral Fracture Assessment	O.N. Diagnostics LLC.	8/3/2018	K171435	For use in spinal visualization and motion analysis for neck and back pain
Surgical Planning Software Version 1.1	Ortho Kinematics Inc.	11/8/2017	K173247	For use in spinal visualization and motion analysis for neck and back pain
VMA System version 3.0	Ortho Kinematics Inc.	8/25/2017	K172327	For use in spinal visualization and motion analysis for neck and back pain
OKI Surgical Planning Software	Ortho Kinematics Inc.	8/22/2017	K171617	For use in spinal visualization and motion analysis for neck and back pain
UNiD Spine Analyzer	MEDICREA INTERNATIONAL	5/24/2017	K170172	For use in spinal visualization and motion analysis for neck and back pain

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

Dynamika	IMAGE ANALYSIS LIMITED	5/17/2017	K161601	For use in spinal visualization and motion analysis for neck and back pain
spineEOS	ONEFIT MEDICAL	4/8/2016	K160407	For use in spinal visualization and motion analysis for neck and back pain
Philips Eleva Workspot with SkyFlow	Philips Medical Systems DMC GmbH	12/22/2015	K153318	For use in spinal visualization and motion analysis for neck and back pain
Centricity Universal Viewer	GE HEALTHCARE	5/26/2015	K150420	For use in spinal visualization and motion analysis for neck and back pain
SPINEDESIGN Spine Surgery Planning (Software Application)	MEDTRONIC SOFAMOR DANEK USA INC.	5/22/2015	K142648	For use in spinal visualization and motion analysis for neck and back pain

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Description

Dynamic spinal visualization is a general term addressing different imaging technologies that simultaneously visualize spine (vertebrae) movements and external body movement. Vertebral motion analysis uses similar imaging as dynamic spinal visualization, with the addition of controlled movement and computerized tracking. These technologies have been proposed for the evaluation of spinal disorders including neck and back pain.

Summary of Evidence

For individuals who have neck or back pain who receive dynamic spinal visualization, the evidence includes comparative trials. Relevant outcomes are test accuracy, symptoms, and functional outcomes. Techniques include digital motion x-rays, cineradiography/videofluoroscopy, or dynamic magnetic resonance imaging (MRI) of the spine and neck. Most available studies compare spine kinetics in patients who had neck or back pain with spine kinetics in healthy controls. In a feasibility

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

study of 21 patients examining dynamic MRI for the detection of spondylolithesis, 3 dynamic MRI protocols demonstrated sensitivities of 68.8% to 78.6% when compared to standard flexion-extension radiographs. No evidence was identified on the effect of this technology on symptoms or functional outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have back or neck pain who receive vertebral motion analysis, the evidence includes comparisons to standard flexion/extension radiographs. Relevant outcomes are test accuracy, symptoms, and functional outcomes. These studies reported that vertebral motion analysis reduces variability in measurement of rotational and translational spine movement compared with standard flexion/extension radiographs. Whether the reduction in variability improves diagnostic accuracy or health outcomes is uncertain. The single study that reported on diagnostic accuracy lacked a true criterion standard, limiting interpretation of findings. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in September 2025 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Xu N, Wang S, Yuan H, et al. Does Dynamic Supine Magnetic Resonance Imaging Improve the Diagnostic Accuracy of Cervical Spondylotic Myelopathy? A Review of the Current Evidence. *World Neurosurg.* Apr 2017; 100: 474-479. PMID 28130164
2. Teyhen DS, Flynn TW, Childs JD, et al. Arthrokinematics in a subgroup of patients likely to benefit from a lumbar stabilization exercise program. *Phys Ther.* Mar 2007; 87(3): 313-25. PMID 17311885

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

3. Ahmadi A, Maroufi N, Behtash H, et al. Kinematic analysis of dynamic lumbar motion in patients with lumbar segmental instability using digital videofluoroscopy. *Eur Spine J*. Nov 2009; 18(11): 1677-85. PMID 19727854
4. Walter WR, Alizai H, Bruno M, et al. Real-time dynamic 3-T MRI assessment of spine kinematics: a feasibility study utilizing three different fast pulse sequences. *Acta Radiol*. Jan 2021; 62(1): 58-66. PMID 32233646
5. Hino H, Abumi K, Kanayama M, et al. Dynamic motion analysis of normal and unstable cervical spines using cineradiography. An in vivo study. *Spine (Phila Pa 1976)*. Jan 15 1999; 24(2): 163-8. PMID 9926388
6. Takayanagi K, Takahashi K, Yamagata M, et al. Using cineradiography for continuous dynamic-motion analysis of the lumbar spine. *Spine (Phila Pa 1976)*. Sep 01 2001; 26(17): 1858-65. PMID 11568694
7. Wong KW, Leong JC, Chan MK, et al. The flexion-extension profile of lumbar spine in 100 healthy volunteers. *Spine (Phila Pa 1976)*. Aug 01 2004; 29(15): 1636-41. PMID 15284509
8. Huneidi M, Jankowski PP, Bouyer B, et al. Contribution of MRI and imaging exams in the diagnosis of lumbar pseudarthrosis. *Orthop Traumatol Surg Res*. Jan 19 2024: 103817. PMID 38246489
9. Shin JJ, Yoo SJ, Kim TW, et al. Radiological and Clinical Significance of Cervical Dynamic Magnetic Resonance Imaging for Cervical Spondylotic Myelopathy. *Neurospine*. Jun 2024; 21(2): 443-454. PMID 38955522
10. Cheng B, Castellvi AE, Davis RJ, et al. Variability in Flexion Extension Radiographs of the Lumbar Spine: A Comparison of Uncontrolled and Controlled Bending. *Int J Spine Surg*. 2016; 10: 20. PMID 27441178
11. Yeager MS, Cook DJ, Cheng BC. Reliability of computer-assisted lumbar intervertebral measurements using a novel vertebral motion analysis system. *Spine J*. Feb 01 2014; 14(2): 274-81. PMID 24239805
12. Davis RJ, Lee DC, Wade C, et al. Measurement Performance of a Computer Assisted Vertebral Motion Analysis System. *Int J Spine Surg*. 2015; 9: 36. PMID 26273554

Policy History

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

02/01/2006 Medical Director review

02/15/2006 Medical Policy Committee review

02/23/2006 Quality Care Advisory Council approval

03/14/2007 Medical Director review

03/21/2007 Medical Policy Committee approval. Rationale updated. Title changed to Dynamic Spinal Visualization. No change to coverage eligibility.

03/05/2010 Medical Policy Committee approval

03/19/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

03/03/2011 Medical Policy Committee review

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

03/16/2011	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/01/2012	Medical Policy Committee review
03/21/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/07/2013	Medical Policy Committee review
03/20/2013	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/06/2014	Medical Policy Committee review
03/19/2014	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2015	Medical Policy Committee review
03/20/2015	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
03/03/2016	Medical Policy Committee review
03/16/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
03/02/2017	Medical Policy Committee review
03/15/2017	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/01/2018	Medical Policy Committee review
03/21/2018	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/02/2018	Coding update
03/07/2019	Medical Policy Committee review
03/20/2019	Medical Policy Implementation Committee approval. Added “and Vertebral Motion Analysis” to the end of the title. Added a coverage statement for vertebral motion analysis to be investigational.
03/05/2020	Medical Policy Committee review
03/11/2020	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2021	Medical Policy Committee review
03/10/2021	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/20/2021	Coding update
03/03/2022	Medical Policy Committee review
03/09/2022	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/02/2023	Medical Policy Committee review
03/08/2023	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

03/07/2024 Medical Policy Committee review
03/13/2024 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/06/2025 Medical Policy Committee review
03/12/2025 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/05/2026 Medical Policy Committee review
03/11/2026 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date: 03/2027

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	0693T, 76120, 76125, 76496, 76499
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into

Dynamic Spinal Visualization and Vertebral Motion Analysis

Policy # 00197

Original Effective Date: 02/23/2006

Current Effective Date: 04/01/2026

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.